Year in review 2012: Asthma and chronic obstructive pulmonary disease

Respirology

Volumn 18, Issue 3, 2013, Pages 565-572

  Yang, Ian A ^a,b   Ko, Fanny W S ^c   Lim, T K ^d   Hancox, Robert J ^e  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

airway biology; asthma; chronic obstructive pulmonary disease; management

Indexed keywords

AIRWAY REMODELING; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COUGHING; CYTOLOGY; DISEASE CONTROL; HUMAN; NONINVASIVE VENTILATION; PALLIATIVE THERAPY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; SARCOIDOSIS;

ASTHMA; DISEASE MANAGEMENT; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY PHYSIOLOGICAL PHENOMENA;

EID: 84875658765     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12049     Document Type: Review

References (73)

1. Akhabir L, Sandford AJ,. Genome-wide association studies for discovery of genes involved in asthma. Respirology 2011; 16: 396-406.
2. Gowers AM, Cullinan P, Ayres JG, et al. Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review. Respirology 2012; 17: 887-898.
3. Havstad SL, Johnson CC, Zoratti EM, et al. Tobacco smoke exposure and allergic sensitization in children: a propensity score analysis. Respirology 2012; 17: 1068-1072.
4. D'Vaz N, Franklin P,. Household smoking, maternal atopy and allergic sensitization in children: is it all academic? Respirology 2012; 17: 1029-1030.
5. Farah CS, Salome CM,. Asthma and obesity: a known association but unknown mechanism. Respirology 2012; 17: 412-421.
6. Shi Z, Dal Grande E, Taylor AW, et al. Association between soft drink consumption and asthma and chronic obstructive pulmonary disease among adults in Australia. Respirology 2012; 17: 363-369.
7. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 2012; 127: 355-360.
8. Davies AR, Hancox RJ,. Induced sputum in asthma: diagnostic and therapeutic implications. Curr. Opin. Pulm. Med. 2012; 19: 60-65.
9. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
10. Choi JS, Jang AS, Park JS, et al. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology 2012; 17: 322-329.
11. Hancox RJ, Cowan DC, Aldridge RE, et al. Asthma phenotypes: consistency of classification using induced sputum. Respirology 2012; 17: 461-466.
12. Bacci E, Latorre M, Cianchetti S, et al. Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol. Respirology 2012; 17: 1199-1206.
13. Fleming L, Tsartsali L, Wilson N, et al. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax 2012; 67: 675-681.
14. Wark P,. Airway inflammation in asthma, a single measurement is not enough. Respirology 2012; 17: 393-394.
15. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-Analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
16. Kim SH, Moon JY, Kwak HJ, et al. Comparison of two exhaled nitric oxide analyzers: the NIOX MINO hand-held electrochemical analyzer and the NOA280i stationary chemiluminescence analyzer. Respirology 2012; 17: 830-834.
17. Ko FW, Hui DS, Leung TF, et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology 2012; 17: 370-378.
18. Coxson HO,. Using computed tomography to measure the site of airflow obstruction. Respirology 2012; 17: 5-6.
19. Kurashima K, Hoshi T, Takayanagi N, et al. Airway dimensions and pulmonary function in chronic obstructive pulmonary disease and bronchial asthma. Respirology 2012; 17: 79-86.
20. Hoshino M, Ohtawa J,. Effects of budesonide/formoterol combination therapy versus budesonide alone on airway dimensions in asthma. Respirology 2012; 17: 639-646.
21. King GG, Farah CS,. Targeting airway remodelling in asthma: the how, what and where? Respirology 2012; 17: 585-587.
22. Sears MR,. The FDA-mandated trial of safety of long-Acting beta-Agonists in asthma: finality or futility? Thorax 2013; 68: 195-198.
23. Brozek JL, Kraft M, Krishnan JA, et al. Long-Acting beta2-Agonist step-off in patients with controlled asthma: systematic review with meta-Analysis. Arch. Intern. Med. 2012; 172: 1365-1375.
24. Ohkura N, Fujimura M, Nakade Y, et al. Heightened cough response to bronchoconstriction in cough variant asthma. Respirology 2012; 17: 964-968.
25. Ryan NM, Birring SS, Gibson PG,. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 1583-1589.
26. Wilsher M, Hopkins R, Zeng I, et al. Prevalence of asthma and atopy in sarcoidosis. Respirology 2012; 17: 285-290.
27. Young LM, Good N, Milne D, et al. The prevalence and predictors of airway hyperresponsiveness in sarcoidosis. Respirology 2012; 17: 653-659.
28. Guan J, Liu XS, Xu YJ, et al. The relationship between the microsatellite D2S388-5 and D2S2232 polymorphisms and chronic obstructive pulmonary disease in the Chinese Kazakh population. Respirology 2013; 18: 303-307.
29. Kinose D, Ogawa E, Hirota T, et al. A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population. Respirology 2012; 17: 164-171.
30. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2011. [Assessed 30 Oct 2012.] Available from URL: http://www.goldcopd.org/
31. Johannessen A, Bakke PS, Hardie JA, et al. Association of exposure to environmental tobacco smoke in childhood with chronic obstructive pulmonary disease and respiratory symptoms in adults. Respirology 2012; 17: 499-505.
32. Ko FW, Hui DS,. Air pollution and chronic obstructive pulmonary disease. Respirology 2012; 17: 395-401.
33. Zeng G, Sun B, Zhong N,. Non-smoking-related chronic obstructive pulmonary disease: a neglected entity? Respirology 2012; 17: 908-912.
34. Bando M, Miyazawa T, Shinohara H, et al. An epidemiological study of the effects of statin use on airflow limitation in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 493-498.
35. Boschetto P, Beghe B, Fabbri LM, et al. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 2012; 17: 422-431.
36. Ito K, Kawayama T, Shoji Y, et al. Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 940-949.
37. McSharry DG, Ryan S, Calverley P, et al. Sleep quality in chronic obstructive pulmonary disease. Respirology 2012; 17: 1119-1124.
38. Teo WS, Tan WS, Chong WF, et al. Economic burden of chronic obstructive pulmonary disease. Respirology 2012; 17: 120-126.
39. Tanabe N, Muro S, Fuseya Y, et al. Peri-diaphragmatic lung volume assessed by computed tomography correlates with quality of life in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 1137-1143.
40. Galban CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat. Med. 2012; 18: 1711-1715.
41. Hill K, Dolmage TE, Woon L, et al. Comparing peak and submaximal cardiorespiratory responses during field walking tests with incremental cycle ergometry in COPD. Respirology 2012; 17: 278-284.
42. Georgiopoulou V,. Laboratory versus field walking tests in moderate COPD: value in simplicity? Respirology 2012; 17: 197-198.
43. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012; 17: 379-389.
44. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 178: 1139-1147.
45. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689-698.
46. Wenzel RP, Fowler AA 3rd, Edmond MB,. Antibiotic prevention of acute exacerbations of COPD. N. Engl. J. Med. 2012; 367: 340-347.
47. Hodge S, Reynolds PN,. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophagesin chronic obstructive pulmonary disease subjects. Respirology 2012; 17: 802-807.
48. Hansbro PM, Jarnicki AG,. Macrolides for macrophages in chronic obstructive pulmonary disease. Respirology 2012; 17: 739-740.
49. Ouanes I, Jalloul F, Ayed S, et al. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction. Respirology 2012; 17: 660-666.
50. Zhang J, Zhao G, Yu X, et al. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology 2012; 17: 715-720.
51. Cafarella PA, Effing TW, Usmani ZA, et al. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012; 17: 627-638.
52. Gjoerup J, Hilberg O, Bendstrup E,. Inhaled mannitol in the treatment of non-cystic fibrosis bronchiectasis in adults. Respirology 2012; 17: 927-932.
53. Depew ZS, Novotny PJ, Benzo RP,. How many steps are enough to avoid severe physical inactivity in patients with chronic obstructive pulmonary disease? Respirology 2012; 17: 1026-1027.
54. Smith TA, Davidson PM, Lam LT, et al. The use of non-invasive ventilation for the relief of dyspnoea in exacerbations of chronic obstructive pulmonary disease; a systematic review. Respirology 2012; 17: 300-307.
55. Patel K, Janssen DJ, Curtis JR,. Advance care planning in COPD. Respirology 2012; 17: 72-78.
56. Yang M, Fu X, Zhang Y, et al. The +252A/G polymorphism in the Lymphotoxin-α gene increases the risk of asthma: a meta-Analysis. Respirology 2012; 17: 1229-1236.
57. Holt PG, Sly PD,. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat. Med. 2012; 18: 726-735.
58. Krishnamoorthy N, Khare A, Oriss TB, et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat. Med. 2012; 18: 1525-1530.
59. Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J. Allergy Clin. Immunol. 2011; 127: 372-381 e1-3.
60. Wilson RH, Maruoka S, Whitehead GS, et al. The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nat. Med. 2012; 18: 1705-1710.
61. Sideleva O, Suratt BT, Black KE, et al. Obesity and asthma. Am. J. Respir. Crit. Care Med. 2012; 186: 598-605.
62. Holgate ST,. Innate and adaptive immune responses in asthma. Nat. Med. 2012; 18: 673-683.
63. Holtzman MJ,. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J. Clin. Invest. 2012; 122: 2741-2748.
64. Chi SY, Ban HJ, Kwon YS, et al. Invariant natural killer T cells in chronic obstructive pulmonary disease. Respirology 2012; 17: 486-492.
65. Koarai A, Yanagisawa S, Sugiura H, et al. Cigarette smoke augments the expression and responses of toll-like receptor 3 in human macrophages. Respirology 2012; 17: 1018-1025.
66. Wang R, Ahmed J, Wang G, et al. Airway epithelial expression of TLR5 is downregulated in healthy smokers and smokers with chronic obstructive pulmonary disease. J. Immunol. 2012; 189: 2217-2225.
67. Grainge C, Dulay V, Ward J, et al. Resistin-like molecule-beta is induced following bronchoconstriction of asthmatic airways. Respirology 2012; 17: 1094-1100.
68. Tuder RM, Petrache I,. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 2012; 122: 2749-2755.
69. Sugiura H, Koarai A, Ichikawa T, et al. Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 533-540.
70. Navratilova Z, Zatloukal J, Kriegova EVA, et al. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 1006-1012.
71. Mohan A, Prasad D, Sharma A, et al. Delayed resolution of inflammatory response compared with clinical recovery in patients with acute exacerbations of chronic obstructive pulmonary disease. Respirology 2012; 17: 1080-1085.
72. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012; 8: e1002824.
73. Kubo H,. Tissue engineering for pulmonary diseases: insights from the laboratory. Respirology 2012; 17: 445-454.